On this page you can find relevant researchs on drug-related health topics, including HIV, hepatitis C, drug and overdose prevention, harm reduction and drug treatment. You can also find our Clinical Guidelines.

National Opioid Pharmacotherapy Statistics Annual Data collection 2019
On a snapshot day in 2019, over 50,000 clients received pharmacotherapy treatment for their opioid dependence at 2,940 dosing points across Australia. There were 3,395 authorised prescribers of opioid pharmacotherapy drugs.
Drug-related hospital emergency presentations in Europe: update from the Euro-DEN Plus expert network
This report presents the latest findings on drug-related hospital emergencies from a network of sentinel hospitals across Europe. Almost 24 000 emergency presentations were recorded at 32 sentinel hospitals over the first 4 years of the project. The data reveal that the substances most commonly involved in acute drug toxicity presentations include heroin, cocaine and cannabis. Prescription medicines are frequently reported. The report also sheds light on other aspects of drug-related emergencies such as clinical features, geographical variation, outcomes, demographics and time patterns.
Drug Decriminalization: A Matter of Justice and Equity, Not Just Health
Since 2016, more than 10,300 Canadians have died of an apparent opioid-related overdose, with the majority involving fentanyl or fentanyl analogs
EMCDDA operating guidelines for the European Union Early Warning System on new psychoactive substances
These guidelines provide the rationale, steps, procedures, roles, and responsibilities for the operation of the EU Early Warning System. They reflect the requirements of Regulation (EC) No 1920/2006 (as amended) and Council Framework Decision 2004/757/JHA (as amended) with respect to information exchange and the early warning system, as well as for the initial report, risk assessment, and control measures.
Series from the Lancet journals on Drug Use
The drug use landscape is dynamic and changing. Changes in public attitudes and laws towards drug use have occurred in an increasing number of countries. Global drug production and consumption are increasing as are the risks and harms to health, while new substances continue to emerge. This Series focuses on opioids, cannabinoids, stimulants, and new psychoactive substances. The Series authors review the evidence on the epidemiology of drug use and related harms and interventions (treatment and policies) to address them. They highlight issues that are likely to become increasingly important in the next decade.
Causes of hospital admission and mortality among 6683 people who use heroin: A cohort study comparing relative and absolute risks
Mortality in high-risk groups such as people who use illicit drugs is often expressed in relative terms such as standardised ratios. These measures are highest for diseases that are rare in the general population, such as hepatitis C, and may understate the importance of common long-term conditions.
Redressing the Balance: How to Reduce Drug-Related Deaths.
There were 4,359 deaths related to drug poisoning in England and Wales in 2018, the highest number and the highest annual increase (16%) since the time series began in 1993. (ONS 2019)
INPUD Statement: HIV2020
The IAS decision to hold the AIDS Conference in the United States shows a disregard for their own organisational values, which include an explicit focus on human rights and inclusivity, whilst encouraging meaningful engagement of people living with HIV and key populations.
First-of-its-kind guideline sets out best practices for delivering injectable opioid agonist treatment
The first-ever Canadian guidelines for prescribing injectable opioid agonist treatment (iOAT) were released today. The clinical guideline provides optimal strategies for delivering iOAT with prescription heroin and hydromorphone for people with severe opioid use disorder.
Monitoring the elimination of viral hepatitis as a public health threat among people who inject drugs in Europe
This technical report focuses on an elimination barometer for viral hepatitis to help countries assess progress towards eliminating hepatitis C and B among people who inject drugs (PWID).
Share this on: